hexokinase d

PF-04937319 is an activator of glucokinase (EC50 =154.4  μM). PF-04937319 maintains glucose-lowering efficacy while mitigating the risk of hypoglycemia observed with many other glucokinase activators. PF-04937319 can be used in research on the treatment of type 2 diabetes mellitus.

Globalagliatin (LY2608204) has been used in trials studying the treatment of Diabetes Mellitus, Type 2.

AMG-3969 is an effective glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor (IC50: 4 nM).

MK-0941 free base is an orally active glucokinase activator with potent glucose-lowering activity, making it a potential therapeutic agent for type 2 diabetes.

Dorzagliatin (HMS5552) is a dual-acting glucokinase (GK) activator. It also improves glycaemic control and pancreatic β-cell function in type 2 diabetes.

Palmitelaidic Acid (trans-Palmitoleic acid) is one of the most abundant fatty acids in serum and tissue.

AZD-1656 is a glucokinase activator (GKA) that can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies and type 2 diabetes.

AM-2394 is an effective and specific Glucokinase agonist (GKA, EC50: 60 nM), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. AM-2394(AM2394) increases the affinity of GK for glucose by approximately 10-fold, exhibits moderate clearance and good oral bioavailability in multiple animal models, and lowers glucose excursion following an oral glucose tolerance test in an ob/ob mouse model of diabetes.

2-Deoxy-D-glucose (2-DG) is an analog of glucose, an inhibitor of glycolysis. 2-Deoxy-D-glucose has antiviral activity, as well as inhibitory cell proliferation and apoptosis-inducing activity.

In cells, D-Glucose 6-phosphate sodium (G6P) is generated when glucose is phosphorylated by hexokinase or glucokinase or by the conversion of glucose-1-phosphate by phosphoglucomutase during glycogenolysis. G6P lies at the beginning of both glycolysis and the pentose phosphate pathways. It also can be stored as glycogen when blood glucose levels are high.

L-Glucose (L-(-)-Glucose), an enantiomer of D-glucose, is not bioavailable to cells as an energy source because it cannot be phosphorylated by hexokinase.

2-Deoxy-D-glucose 6-phosphate sodium is a derivative of 2-Deoxy-D-glucose, produced in mammalian cells by the action of hexokinase on 2-DG. 2-Deoxy-D-glucose acts as a competitive inhibitor of glucose metabolism, inhibiting glycolysis through its effect on hexokinase.

2-deoxy-D-Glucose-13C is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose (T6742) is a glucose antimetabolite and an inhibitor of glycolysis. It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.

In cells, D-Glucose 6-phosphate potassium salt (G6P) is generated when glucose is phosphorylated by hexokinase or glucokinase or by the conversion of glucose-1-phosphate by phosphoglucomutase during glycogenolysis. G6P lies at the beginning of both glycolysis and the pentose phosphate pathways. It also can be stored as glycogen when blood glucose levels are high.

2-Deoxy-D-glucose 6-phosphate disodium is a glucose analog that inhibits glycolysis and inhibits the function of hexokinase and glucose-6-phosphate isomerase.

2-Deoxy-D-glucose-D is the deuterated form of 2-Deoxy-D-glucose (T6742). This compound is a glucose analogue that acts as a glucose metabolism inhibitor by targeting hexokinase to hinder glycolysis.

2-Deoxy-D-glucose-13C6 is a 13C-labeled variant of 2-Deoxy-D-glucose. As a glucose analog, 2-Deoxy-D-glucose (T6742) functions as a glucose metabolism inhibitor by targeting hexokinase, thereby disrupting glycolysis.